Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Eligibility criteria
Qualifiers
Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
Family history of pancreatic ductal adenocarcinoma (PDAC)
Disqualifiers
BMI < 18.5 Kg/m2
Documented history of symptomatic hypoglycemia
Pregnant or breastfeeding women
Cognitively impaired individuals
Trial design
Treatments tested in this trial
- intermittent fasting
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov